Zhong Lun advised LaNova Medicines in Completing its CNY 300 Million Series C1 Financing and Entering into Strategic Collaboration with Sino Biopharm. LaNova Medicines Technology (Shanghai)...
You must be a Standard 1 Year member to access this content.
Gibson Dunn & Crutcher advised Merck on the transaction and Wilson Sonsini Goodrich & Rosati advised LaNova Medicines. Merck (NYSE: MRK), known as MSD outside of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised LaNova on the deal. Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel targeted therapies for...
You must be a Standard 1 Year member to access this content.
